Meta description: Bioxodes secures €5.5 million in Series A extension funding, bringing total raised to €17.5 million, to prepare BIOX-101 for Phase 2b trial in 2027.
Bioxodes SA has closed a €5.5 million Series A extension round, adding to its previously raised capital and bringing total Series A financing to approximately €17.5 million. The fresh capital will support preparations for a pivotal Phase 2b clinical trial of BIOX-101 in intracerebral hemorrhage (ICH), targeted to start in 2027. Newton Biocapital joined as a new investor alongside strong participation from existing backers. The projected commercial launch could happen as early as the second half of 2030, subject to regulatory approvals.
- Who invested in this round?
- What does this mean for growth?
- What are the next funding and trial milestones?
- FAQ
- Key takeaways
- Disclaimer
- Announcement note
Who invested in this round?
The €5.5 million raised in the Series A extension came from a mix of new and existing investors. Notably, Newton Biocapital, a life science venture capital firm with expertise in early-stage European and Japanese companies, entered the shareholder base. Other current investors also took part, reflecting confidence in Bioxodes’ clinical progress and commercial potential.
With this extension, the Series A total reaches around €17.5 million. This capital has been earmarked for clinical trial readiness and regulatory engagement ahead of the Phase 2b trial launch in 2027.
What does this mean for growth?
The funding allows Bioxodes to maintain momentum toward late-stage trials without operational delays. BIOX-101, the company’s lead stroke therapy candidate, has already demonstrated positive safety and efficacy signals in the earlier Phase 2a trial. These results, supported by the unanimous recommendation from the Data Monitoring Committee, give the company a strong foundation for advancing toward potential registration trials.
If timelines hold, and regulatory pathways proceed smoothly, conditional marketing authorisations could be sought in the US by late 2030 and in Europe by early 2031. The dual-action nature of BIOX-101 offers a competitive advantage in addressing unmet needs in ICH, a condition with high morbidity and mortality.
What are the next funding and trial milestones?
Beyond the Phase 2b trial in ICH, Bioxodes is preparing to run Phase 2 studies of BIOX-101 in acute ischemic stroke and an undisclosed indication. To finance this broader clinical pipeline, the company has initiated discussions for a €80 million Series B round. Strategic partnering conversations are also underway, which could provide additional capital and commercial synergies.
The company’s cash planning ties into a long-term growth trajectory, balancing late-stage clinical development with potential earlier market entry through conditional approvals.
FAQ
1. How much has Bioxodes raised in total Series A funding?
Approximately €17.5 million including the original round and this €5.5 million extension.
2. Who is the new investor in this round?
Newton Biocapital, a life science venture capital firm focusing on early-stage investments in Europe and Japan.
3. When will the pivotal Phase 2b trial start?
The trial is scheduled for initiation in 2027.
4. When could BIOX-101 reach the market?
The earliest projected commercial launch is the second half of 2030, subject to regulatory review.
5. What is planned after the Phase 2b trial?
Additional Phase 2 trials in acute ischemic stroke and another undisclosed indication, funded partly by a planned €80 million Series B round.
Key takeaways
For founders and investors, Bioxodes’ Series A extension shows strategic timing in clinical funding. The inclusion of a specialist new investor and strong support from existing backers suggests continued confidence in the product’s market potential. The dual pathway of raising capital while expanding trial scope positions the company for meaningful valuation growth if clinical milestones are met.
Disclaimer
This content is provided for informational purposes only and does not constitute financial advice, investment guidance, or a solicitation to buy or sell securities.